ORIC Quote, Financials, Valuation and Earnings

Perspective Therapeutics has a net margin of -- compared to ORIC Pharmaceuticals's net margin of --. ORIC Pharmaceuticals's return on equity of -- beat Perspective Therapeutics's return on equity of --.

ORIC Pharmaceuticals has a consensus price target of $19.00, signalling upside risk potential of 305.12%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 677.99%. Given that Perspective Therapeutics has higher upside potential than ORIC Pharmaceuticals, analysts believe Perspective Therapeutics is more attractive than ORIC Pharmaceuticals.

ORIC Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

ORIC Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ORIC Pharmaceuticals pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

ORIC Pharmaceuticals quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. ORIC Pharmaceuticals's net income of -$36.3M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, ORIC Pharmaceuticals's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ORIC Pharmaceuticals is -- versus 11.98x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Johnson & Johnson has a net margin of -- compared to ORIC Pharmaceuticals's net margin of 50.24%. ORIC Pharmaceuticals's return on equity of -- beat Johnson & Johnson's return on equity of 19.98%.

ORIC Pharmaceuticals has a consensus price target of $19.00, signalling upside risk potential of 305.12%. On the other hand Johnson & Johnson has an analysts' consensus of $170.21 which suggests that it could grow by 10.59%. Given that ORIC Pharmaceuticals has higher upside potential than Johnson & Johnson, analysts believe ORIC Pharmaceuticals is more attractive than Johnson & Johnson.

ORIC Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Johnson & Johnson has a beta of 0.490, suggesting its less volatile than the S&P 500 by 50.995%.

ORIC Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Johnson & Johnson offers a yield of 3.22% to investors and pays a quarterly dividend of $1.24 per share. ORIC Pharmaceuticals pays -- of its earnings as a dividend. Johnson & Johnson pays out 84.05% of its earnings as a dividend. Johnson & Johnson's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ORIC Pharmaceuticals quarterly revenues are --, which are smaller than Johnson & Johnson quarterly revenues of $21.9B. ORIC Pharmaceuticals's net income of -$36.3M is lower than Johnson & Johnson's net income of $11B. Notably, ORIC Pharmaceuticals's price-to-earnings ratio is -- while Johnson & Johnson's PE ratio is 17.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ORIC Pharmaceuticals is -- versus 4.18x for Johnson & Johnson. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of -- compared to ORIC Pharmaceuticals's net margin of -49.65%. ORIC Pharmaceuticals's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ORIC Pharmaceuticals has a consensus price target of $19.00, signalling upside risk potential of 305.12%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 44.56%. Given that ORIC Pharmaceuticals has higher upside potential than NovaBay Pharmaceuticals, analysts believe ORIC Pharmaceuticals is more attractive than NovaBay Pharmaceuticals.

ORIC Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

ORIC Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ORIC Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ORIC Pharmaceuticals quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ORIC Pharmaceuticals's net income of -$36.3M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, ORIC Pharmaceuticals's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ORIC Pharmaceuticals is -- versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

ENDRA Life Sciences has a net margin of -- compared to ORIC Pharmaceuticals's net margin of --. ORIC Pharmaceuticals's return on equity of -- beat ENDRA Life Sciences's return on equity of --.

ORIC Pharmaceuticals has a consensus price target of $19.00, signalling upside risk potential of 305.12%. On the other hand ENDRA Life Sciences has an analysts' consensus of $2,625.00 which suggests that it could grow by 78258.29%. Given that ENDRA Life Sciences has higher upside potential than ORIC Pharmaceuticals, analysts believe ENDRA Life Sciences is more attractive than ORIC Pharmaceuticals.

ORIC Pharmaceuticals has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison ENDRA Life Sciences has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.328%.

ORIC Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ENDRA Life Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ORIC Pharmaceuticals pays -- of its earnings as a dividend. ENDRA Life Sciences pays out -- of its earnings as a dividend.

ORIC Pharmaceuticals quarterly revenues are --, which are smaller than ENDRA Life Sciences quarterly revenues of --. ORIC Pharmaceuticals's net income of -$36.3M is lower than ENDRA Life Sciences's net income of -$2.4M. Notably, ORIC Pharmaceuticals's price-to-earnings ratio is -- while ENDRA Life Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ORIC Pharmaceuticals is -- versus 2.56x for ENDRA Life Sciences. Usually stocks with elevated PS ratios are considered overvalued.